Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Real-life use of trametinib after immunotherapy failure in BRAF wild-type advanced melanoma.

Melanoma research - 1 Jun 2023

Pigné Tristan, Lévy Marie, Ducharme Océane, Dutriaux Caroline, Gerard Emilie, Pham-Ledard Anne, Beylot-Barry Marie, Prey Sorilla

Abstract excerpt

BRAF V600 wild-type advanced melanomas quickly reach a therapeutic dead-end, after immunotherapy failure. Even if preclinical studies have suggested sensitivity to MEK inhibitors such as trametinib in NRAS, NF1 or GNA mutated melanoma, therapeutic options are limited for these patients. We present a retrospective monocentric study of 22 patients with advanced melanoma treated by trametinib after immunotherapy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immunotherapy
Share to Melanoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Oximes

Share to Proto-Oncogene Proteins B-raf

Share to Pyridones

Share to Pyrimidinones

Share to Quality of Life

Share to Skin Neoplasms

Source

Identifiers

PMID: 36919691
DOI: 10.1097/CMR.0000000000000884

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Real-life use of trametinib after immunotherapy failure in BRAF wild-type advanced melanoma.PMID 36919691Read ↗

Combined therapy with dabrafenib and trametinib in BRAF-mutated metastatic melanoma in a real-life setting: the INT Milan experience.Semantic proximity Read ↗

MEK inhibitors for pre-treated, NRAS-mutated metastatic melanoma: A multi-centre, retrospective study.Semantic proximity Read ↗

Trametinib in the treatment of melanoma.Semantic proximity Read ↗

Phase II Clinical Trial of Trametinib and Low-Dose Dabrafenib in Advanced, Previously Treated BRAFV600/NRASQ61 Wild-Type Melanoma (TraMel-WT)Semantic proximity Read ↗

Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.Semantic proximity Read ↗

Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial.Semantic proximity Read ↗

[BRAF-MEK inhibitor therapy in melanoma].Semantic proximity Read ↗

Dabrafenib-trametinib combination in 'field-practice': an Italian experience.Semantic proximity Read ↗

Improved survival with MEK inhibition in BRAF-mutated melanoma.Semantic proximity Read ↗

Vemurafenib/dabrafenib and trametinibSemantic proximity Read ↗

Combination dabrafenib and trametinib in the management of advanced melanoma with BRAFV600 mutations.Semantic proximity Read ↗

Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF (V600) Mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.